Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History AXSM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics AXSM

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Axsome Therapeutics Inc

AXSM
Current price
108.98 USD -1.75 USD (-1.58%)
Last closed 110.73 USD
ISIN US05464T1043
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 5 451 946 496 USD
Yield for 12 month +31.62 %
1Y
3Y
5Y
10Y
15Y
AXSM
21.11.2021 - 28.11.2021

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York. Address: One World Trade Center, New York, NY, United States, 10007

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

177.05 USD

P/E Ratio

Dividend Yield

Financials AXSM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures AXSM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+385 693 000 USD

Last Year

+270 600 000 USD

Current Quarter

+121 463 000 USD

Last Quarter

+118 766 000 USD

Current Year

+352 390 000 USD

Last Year

+244 535 000 USD

Current Quarter

+111 674 000 USD

Last Quarter

+108 252 000 USD
EBITDA -230 960 992 USD
Operating Margin TTM -45.67 %
Price to Earnings
Return On Assets TTM -26.17 %
PEG Ratio
Return On Equity TTM -282.16 %
Wall Street Target Price 177.05 USD
Revenue TTM 432 156 992 USD
Book Value 1.08 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 62.00 %
Dividend Yield
Gross Profit TTM 395 361 984 USD
Earnings per share -5.77 USD
Diluted Eps TTM -5.77 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -64.39 %

Stock Valuation AXSM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 12.59
Price Sales TTM 12.62
Enterprise Value EBITDA -14.81
Price Book MRQ 103.97

Technical Indicators AXSM

For 52 Weeks

72.21 USD 139.13 USD
50 Day MA 107.01 USD
Shares Short Prior Month 4 018 501
200 Day MA 103.38 USD
Short Ratio 6.45
Shares Short 4 083 784
Short Percent 9.75 %